Korea Pharma to Launch Digital Therapeutic Device for Children with ADHD... Full-Scale Market Entry

On November 7, Korea Pharma announced that it will collaborate with Emotive, a company specializing in digital therapeutics, to launch a non-pharmaceutical digital therapeutic device for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children. The digital therapeutic device to be introduced by the two companies is a game-based cognitive training solution designed based on cognitive modeling. It is intended to help improve children's attention span and concentration. This device has already secured clinical evidence, and its application is expected to expand in medical settings both in Korea and abroad. At the Autumn Academic Conference of the Korean Academy of Child and Adolescent Psychiatry held on the same day, the two companies will showcase the product at a joint booth, marking the start of their marketing activities. Korea Pharma is expanding its business beyond its existing portfolio focused on central nervous system (CNS) pharmaceuticals to the digital-based

Stock Disclosure

11.07 10:27

CJ Logistics Reports Q3 Operating Profit of 147.9 Billion Won, Up 4.4% Year-on-Year

CJ Logistics announced on the 7th that its provisional operating profit for the third quarter of this year reached 147.9 billion won, marking a 4.4% increase compared to the same period last year. During the same period, sales rose by 3.1% to 3.0666 trillion won. By business segment, the parcel delivery (O-NE) division recorded sales of 965 billion won, up 7.4% year-on-year, while operating profit increased by 16.6% to 62.8 billion won. Since June, parcel volume has rebounded due to the recovery of consumer sentiment and the effect of the seven-day-a-week delivery service "Maeil One," alongside expanded sales from new businesses such as same-day and early-morning delivery and fulfillment services. The contract logistics (CL) business achieved sales of 861.3 billion won and operating profit of 55.3 billion won, representing increases of 12.1% and 7.8%, respectively, compared to the same period last year. The company attributed this to the expansion of new orders in third-party logistic

Stock Disclosure

11.07 09:03

[Click e-Stock] "WSI's Medical AI Robot Business Enters Full Growth Trajectory"

On November 7, KB Securities analyzed that WSI is accelerating its two-track growth strategy, focusing on the development of medical AI robots and the distribution of cardiovascular medical devices as its two main pillars. Kim Hyungyeom, a researcher at KB Securities, stated, "Through the two-track strategy of developing innovative medical AI robots and expanding the high-growth cardiovascular medical device distribution business, WSI is securing a stable revenue base and future growth drivers, which warrants attention." In the first half of this year, WSI recorded sales of 25.81 billion won, up 58.7% from the same period last year. Operating profit was 2.16 billion won, an increase of 10.0%. The performance of Introbio Pharma was reflected, resulting in significant sales growth; however, profitability slightly weakened due to increased selling and administrative expenses from expanded R&D investment and workforce expansion. Researcher Kim explained, "The medical AI robot business of s

Stock Disclosure

11.07 08:59

[Click e-Stock] "Hecto Innovation Achieves Record-High Sales for Six Consecutive Quarters... Healthcare Growth in Focus"

Eugene Investment & Securities stated on November 7 that Hecto Innovation "has continued its growth by achieving record-high quarterly sales for six consecutive quarters," adding, "We are particularly noting the strong performance growth in the healthcare division." In a report released that day, Eugene Investment & Securities researcher Park Jongseon analyzed, "The company's preliminary consolidated results for the third quarter this year show sales of 95.6 billion won and operating profit of 14.7 billion won, representing increases of 19.2% and 5.4%, respectively, compared to the same period last year." He added, "All business divisions maintained growth, setting new record-high quarterly sales for six straight quarters, while profitability also remained at a solid level." Park further explained, "The drivers of sales growth were increases of 5.4%, 11.9%, and 67.2% year-on-year in the IT information services, fintech, and healthcare divisions, respectively." He continued, "In particu

Stock Disclosure

11.07 08:45

Daejin Advanced Materials Indicted Despite No Involvement in 'Technology Leakage'... "Excessive Investigation Ignores National Economy, Strong Regret"

Global advanced materials company Daejin Advanced Materials expressed strong regret on November 7, stating, "It is a clear case of excessive investigation and an unfair decision to indict the company without detention, treating an unrelated company as if it were involved in a crime, solely due to the former CEO's case during the prosecution's recent 'technology leakage' investigation." Daejin Advanced Materials pointed out, "The technology in question by the prosecution has no connection whatsoever to the technologies we currently produce or possess," and added, "It is legally unacceptable to indict a company unrelated to the case based solely on the major shareholder’s equity relationship." The company strongly criticized, "The prosecution’s decision to indict the corporation due to the former CEO’s past position is a typical example of the abuse of the 'dual punishment provision.'" The company further stated, "We have fully cooperated transparently with all requests from investigativ

Stock Disclosure

11.07 08:40

[Click e-Stock] "CJ ENM, Profit Volatility Remains... Clearer Investment Points Needed"

On November 7, Hanwha Investment & Securities pointed out that “quarterly profit volatility remains high for CJ ENM due to investment costs for securing growth drivers and the burden of investments to strengthen overseas business,” adding, “It is a time when more distinct investment points are needed.” Kim So-hye, an analyst at Hanwha Investment & Securities, made this assessment on the same day, maintaining a ‘Buy’ rating and a target price of 72,000 won for CJ ENM. CJ ENM’s third-quarter results this year recorded 1.25 trillion won in revenue and 17.6 billion won in operating profit, falling significantly short of market expectations. In particular, the media platform segment posted an operating loss of 3.3 billion won. Analyst Kim explained, “Despite high viewership ratings and the popularity of major content, TV advertising sales decreased by as much as 27.1% compared to the same period last year.” Looking at the performance by major segment, Tving recorded an operating loss of 16.

Stock Disclosure

11.07 08:24

[Click e-Stock] "Cosmecca Korea Maintains Earnings Momentum... Target Price Raised"

On November 7, Daishin Securities raised its target price for Cosmecca Korea from 90,000 won to 100,000 won, citing expectations of continued top-line growth. The investment opinion was maintained at 'Buy'. Jung Hansol, a researcher at Daishin Securities, stated, "We have raised our earnings estimates and increased the target price by 11% as we expect continued top-line growth. The earnings momentum remains solid due to last year's low base and ongoing order expansion. In particular, products manufactured by Cosmecca Korea have established themselves as hit products by maintaining high rankings overseas, which increases the likelihood of continued large-volume orders from major clients of the Korean subsidiary." In the third quarter of this year, Cosmecca Korea recorded 82.4 billion won in sales, up 44% year-on-year, and 27.2 billion won in operating profit, up 79%. Researcher Jung analyzed, "The company delivered outstanding results, significantly exceeding consensus (the average of s

Stock Disclosure

11.07 07:57

[Click eStock] "TCK Expected to Achieve Record-High Results Next Year... Target Price Raised"

Yuanta Securities analyzed on November 7 that TCK is expected to achieve record-high results next year. The firm maintained its "Buy" investment rating and raised its target price to 224,000 won. Yuanta Securities projected that TCK's sales and operating profit next year will reach 380 billion won and 116.5 billion won, respectively, representing year-on-year increases of 21.5% and 31.4%. Baek Gilhyeon, a researcher at Yuanta Securities, stated, "The global NAND demand bit growth rate in 2026 is estimated at 17.1%, which is an expansion in growth compared to the previous year," adding, "Record-high performance is expected due to increased demand from Chinese customers compared to last year." He further emphasized, "Considering the current production capacity and utilization rate at the Anseong plant, it is expected that the company will complete the purchase of a new site in Anseong within this year and begin ordering CVD chambers to secure additional capacity." He added, "The new site

Stock Disclosure

11.07 07:57

[This Week's IPO] Book-Building and Subscription Schedule for the Second Week of November

Korea Pharma to Launch Digital Therapeutic Device for Children with ADHD... Full-Scale Market Entry

CJ Logistics Reports Q3 Operating Profit of 147.9 Billion Won, Up 4.4% Year-on-Year

[Click e-Stock] "WSI's Medical AI Robot Business Enters Full Growth Trajectory"

[Click e-Stock] "Hecto Innovation Achieves Record-High Sales for Six Consecutive Quarters... Healthcare Growth in Focus"

Daejin Advanced Materials Indicted Despite No Involvement in 'Technology Leakage'... "Excessive Investigation Ignores National Economy, Strong Regret"

[Click e-Stock] "CJ ENM, Profit Volatility Remains... Clearer Investment Points Needed"

[Click e-Stock] "Cosmecca Korea Maintains Earnings Momentum... Target Price Raised"

[Click eStock] "TCK Expected to Achieve Record-High Results Next Year... Target Price Raised"

Special Coverage

In the News